Monoclonal antibodies (mAbs) Biosimilars Market Report

China Monoclonal antibodies (mAbs) Biosimilars Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Aug 21, 2022
  • PAGES：196
  • REPORT CODE：GMM1076835
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.

    This report offers an overview of the market trends, drivers, and barriers with respect to the China Monoclonal antibodies (mAbs) Biosimilars market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Monoclonal antibodies (mAbs) Biosimilars market. Detailed analysis of key players, along with key growth strategies adopted by Monoclonal antibodies (mAbs) Biosimilars industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • AET Biotech

    • Celltrion

    • Dr Reddy's Laboratories

    • Allergan

    • Accord Healthcare

    • Amega Biotech

    • Biocon

    • 3SBio

    • Others

    • Hospira

    By Type:

    • Erythropoietin (EPO)

    • Human Growth Hormone (HGH)

    • Granulocyte- Colony Stimulating Factor (G-CSF)

    • Monoclonal Antibody (mAb)

    • Insulin

    • Interferon (IFN)

    • Hospira

    By End-User:

    • Anti-Cancer

    • Anti-Inflammatory/Autoimmune

    By Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Monoclonal antibodies (mAbs) Biosimilars Market

    • 1.3 Market Segment by Type

    • 1.3.1 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Erythropoietin (EPO) from 2016 to 2027

    • 1.3.2 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Human Growth Hormone (HGH) from 2016 to 2027

    • 1.3.3 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Granulocyte- Colony Stimulating Factor (G-CSF) from 2016 to 2027

    • 1.3.4 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Monoclonal Antibody (mAb) from 2016 to 2027

    • 1.3.5 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Insulin from 2016 to 2027

    • 1.3.6 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Interferon (IFN) from 2016 to 2027

    • 1.3.7 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Hospira from 2016 to 2027

    • 1.4 Market Segment by Application

    • 1.4.1 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Anti-Cancer from 2016 to 2027

    • 1.4.2 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Anti-Inflammatory/Autoimmune from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 North China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 South China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 East China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.5 Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.6 Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.7 Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Monoclonal antibodies (mAbs) Biosimilars Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Monoclonal antibodies (mAbs) Biosimilars by Major Types

    • 3.4.1 Market Size and Growth Rate of Erythropoietin (EPO)

    • 3.4.2 Market Size and Growth Rate of Human Growth Hormone (HGH)

    • 3.4.3 Market Size and Growth Rate of Granulocyte- Colony Stimulating Factor (G-CSF)

    • 3.4.4 Market Size and Growth Rate of Monoclonal Antibody (mAb)

    • 3.4.5 Market Size and Growth Rate of Insulin

    • 3.4.6 Market Size and Growth Rate of Interferon (IFN)

    • 3.4.7 Market Size and Growth Rate of Hospira

    4 Segmentation of Monoclonal antibodies (mAbs) Biosimilars Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Monoclonal antibodies (mAbs) Biosimilars by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Monoclonal antibodies (mAbs) Biosimilars in Anti-Cancer

    • 4.4.2 Market Size and Growth Rate of Monoclonal antibodies (mAbs) Biosimilars in Anti-Inflammatory/Autoimmune

    5 Market Analysis by Regions

    • 5.1 China Monoclonal antibodies (mAbs) Biosimilars Production Analysis by Regions

    • 5.2 China Monoclonal antibodies (mAbs) Biosimilars Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on China Economy

    6 North China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 6.1 North China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 6.2 North China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    7 Central China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 7.1 Central China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 7.2 Central China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    8 South China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 8.1 South China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 8.2 South China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    9 East China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 9.1 East China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 9.2 East China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    10 Northeast China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 10.1 Northeast China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 10.2 Northeast China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    11 Southwest China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 11.1 Southwest China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 11.2 Southwest China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    12 Northwest China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis

    • 12.1 Northwest China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major Types

    • 12.2 Northwest China Monoclonal antibodies (mAbs) Biosimilars Landscape Analysis by Major End-Users

    13 Major Players Profiles

    • 13.1 AET Biotech

      • 13.1.1 AET Biotech Company Profile and Recent Development

      • 13.1.2 Market Performance

      • 13.1.3 Product and Service Introduction

    • 13.2 Celltrion

      • 13.2.1 Celltrion Company Profile and Recent Development

      • 13.2.2 Market Performance

      • 13.2.3 Product and Service Introduction

    • 13.3 Dr Reddy's Laboratories

      • 13.3.1 Dr Reddy's Laboratories Company Profile and Recent Development

      • 13.3.2 Market Performance

      • 13.3.3 Product and Service Introduction

    • 13.4 Allergan

      • 13.4.1 Allergan Company Profile and Recent Development

      • 13.4.2 Market Performance

      • 13.4.3 Product and Service Introduction

    • 13.5 Accord Healthcare

      • 13.5.1 Accord Healthcare Company Profile and Recent Development

      • 13.5.2 Market Performance

      • 13.5.3 Product and Service Introduction

    • 13.6 Amega Biotech

      • 13.6.1 Amega Biotech Company Profile and Recent Development

      • 13.6.2 Market Performance

      • 13.6.3 Product and Service Introduction

    • 13.7 Biocon

      • 13.7.1 Biocon Company Profile and Recent Development

      • 13.7.2 Market Performance

      • 13.7.3 Product and Service Introduction

    • 13.8 3SBio

      • 13.8.1 3SBio Company Profile and Recent Development

      • 13.8.2 Market Performance

      • 13.8.3 Product and Service Introduction

    • 13.9 Others

      • 13.9.1 Others Company Profile and Recent Development

      • 13.9.2 Market Performance

      • 13.9.3 Product and Service Introduction

    • 13.10 Hospira

      • 13.10.1 Hospira Company Profile and Recent Development

      • 13.10.2 Market Performance

      • 13.10.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Erythropoietin (EPO) from 2016 to 2027

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Human Growth Hormone (HGH) from 2016 to 2027

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Granulocyte- Colony Stimulating Factor (G-CSF) from 2016 to 2027

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Monoclonal Antibody (mAb) from 2016 to 2027

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Insulin from 2016 to 2027

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Interferon (IFN) from 2016 to 2027

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Hospira from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2021

    • Figure Market Share by Type in 2027

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Anti-Cancer from 2016 to 2027

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Market Size and Growth Rate of Anti-Inflammatory/Autoimmune from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2021

    • Figure Market Share by End-User in 2027

    • Figure North China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure East China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Monoclonal antibodies (mAbs) Biosimilars Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2020

    • Figure Market Share of TOP 5 Players in 2021

    • Figure Market Share of TOP 6 Players from 2016 to 2021

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Map of China

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Monoclonal antibodies (mAbs) Biosimilars

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Monoclonal antibodies (mAbs) Biosimilars by Different Types from 2016 to 2027

    • Table Consumption Share of Monoclonal antibodies (mAbs) Biosimilars by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Erythropoietin (EPO)

    • Figure Market Size and Growth Rate of Human Growth Hormone (HGH)

    • Figure Market Size and Growth Rate of Granulocyte- Colony Stimulating Factor (G-CSF)

    • Figure Market Size and Growth Rate of Monoclonal Antibody (mAb)

    • Figure Market Size and Growth Rate of Insulin

    • Figure Market Size and Growth Rate of Interferon (IFN)

    • Figure Market Size and Growth Rate of Hospira

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Monoclonal antibodies (mAbs) Biosimilars by Different End-Users from 2016 to 2027

    • Table Consumption Share of Monoclonal antibodies (mAbs) Biosimilars by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Anti-Cancer

    • Figure Market Size and Growth Rate of Anti-Inflammatory/Autoimmune

    • Table China Monoclonal antibodies (mAbs) Biosimilars Production by Regions

    • Table China Monoclonal antibodies (mAbs) Biosimilars Production Share by Regions

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Production Share by Regions in 2016

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Production Share by Regions in 2021

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Production Share by Regions in 2027

    • Table China Monoclonal antibodies (mAbs) Biosimilars Consumption by Regions

    • Table China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Regions

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Regions in 2016

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Regions in 2021

    • Figure China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Regions in 2027

    • Table North China Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2016 to 2027

    • Table North China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2016 to 2027

    • Figure North China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2016

    • Figure North China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2021

    • Figure North China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2027

    • Table North China Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2016 to 2027

    • Table North China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2016 to 2027

    • Figure North China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2016

    • Figure North China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2021

    • Figure North China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2027

    • Table Central China Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2016 to 2027

    • Table Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2016 to 2027

    • Figure Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2016

    • Figure Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2021

    • Figure Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2027

    • Table Central China Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2016 to 2027

    • Table Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2016 to 2027

    • Figure Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2016

    • Figure Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2021

    • Figure Central China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2027

    • Table South China Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2016 to 2027

    • Table South China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2016 to 2027

    • Figure South China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2016

    • Figure South China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2021

    • Figure South China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2027

    • Table South China Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2016 to 2027

    • Table South China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2016 to 2027

    • Figure South China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2016

    • Figure South China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2021

    • Figure South China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2027

    • Table East China Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2016 to 2027

    • Table East China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2016 to 2027

    • Figure East China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2016

    • Figure East China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2021

    • Figure East China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2027

    • Table East China Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2016 to 2027

    • Table East China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2016 to 2027

    • Figure East China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2016

    • Figure East China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2021

    • Figure East China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2027

    • Table Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2016 to 2027

    • Table Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2016 to 2027

    • Figure Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2016

    • Figure Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2021

    • Figure Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2027

    • Table Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2016 to 2027

    • Table Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2016

    • Figure Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2021

    • Figure Northeast China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2027

    • Table Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2016 to 2027

    • Table Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2016 to 2027

    • Figure Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2016

    • Figure Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2021

    • Figure Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2027

    • Table Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2016 to 2027

    • Table Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2016 to 2027

    • Figure Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2016

    • Figure Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2021

    • Figure Southwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2027

    • Table Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption by Types from 2016 to 2027

    • Table Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types from 2016 to 2027

    • Figure Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2016

    • Figure Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2021

    • Figure Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by Types in 2027

    • Table Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption by End-Users from 2016 to 2027

    • Table Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users from 2016 to 2027

    • Figure Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2016

    • Figure Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2021

    • Figure Northwest China Monoclonal antibodies (mAbs) Biosimilars Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of AET Biotech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AET Biotech

    • Figure Sales and Growth Rate Analysis of AET Biotech

    • Figure Revenue and Market Share Analysis of AET Biotech

    • Table Product and Service Introduction of AET Biotech

    • Table Company Profile and Development Status of Celltrion

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Celltrion

    • Figure Sales and Growth Rate Analysis of Celltrion

    • Figure Revenue and Market Share Analysis of Celltrion

    • Table Product and Service Introduction of Celltrion

    • Table Company Profile and Development Status of Dr Reddy's Laboratories

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dr Reddy's Laboratories

    • Figure Sales and Growth Rate Analysis of Dr Reddy's Laboratories

    • Figure Revenue and Market Share Analysis of Dr Reddy's Laboratories

    • Table Product and Service Introduction of Dr Reddy's Laboratories

    • Table Company Profile and Development Status of Allergan

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan

    • Figure Sales and Growth Rate Analysis of Allergan

    • Figure Revenue and Market Share Analysis of Allergan

    • Table Product and Service Introduction of Allergan

    • Table Company Profile and Development Status of Accord Healthcare

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Accord Healthcare

    • Figure Sales and Growth Rate Analysis of Accord Healthcare

    • Figure Revenue and Market Share Analysis of Accord Healthcare

    • Table Product and Service Introduction of Accord Healthcare

    • Table Company Profile and Development Status of Amega Biotech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amega Biotech

    • Figure Sales and Growth Rate Analysis of Amega Biotech

    • Figure Revenue and Market Share Analysis of Amega Biotech

    • Table Product and Service Introduction of Amega Biotech

    • Table Company Profile and Development Status of Biocon

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biocon

    • Figure Sales and Growth Rate Analysis of Biocon

    • Figure Revenue and Market Share Analysis of Biocon

    • Table Product and Service Introduction of Biocon

    • Table Company Profile and Development Status of 3SBio

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of 3SBio

    • Figure Sales and Growth Rate Analysis of 3SBio

    • Figure Revenue and Market Share Analysis of 3SBio

    • Table Product and Service Introduction of 3SBio

    • Table Company Profile and Development Status of Others

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Others

    • Figure Sales and Growth Rate Analysis of Others

    • Figure Revenue and Market Share Analysis of Others

    • Table Product and Service Introduction of Others

    • Table Company Profile and Development Status of Hospira

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Hospira

    • Figure Sales and Growth Rate Analysis of Hospira

    • Figure Revenue and Market Share Analysis of Hospira

    • Table Product and Service Introduction of Hospira


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US